IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance

IDEXX LABORATORIES INC /DE

2021-Q2 EPS reported $4.69 revenue$1,603,849,000

EPS of $2.34, up 36% as reported and 33% comparable basis.
CAG Diagnostics recurring revenue grew 30% reported, 26% organic.
2021 revenue guidance raised to $3,170M-$3,205M (17%-18.5% reported growth).
2021 EPS outlook raised to $8.20-$8.36; operating margin forecast 28.6%-29.1%.
U.S. same-store clinical visit growth 13% in Q2; premium instrument placements doubled YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.